Literature DB >> 19074900

Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.

Wooin Lee1, Abbes Belkhiri, A Craig Lockhart, Nipun Merchant, Hartmut Glaeser, Elizabeth I Harris, M Kay Washington, Elizabeth M Brunt, Alex Zaika, Richard B Kim, Wael El-Rifai.   

Abstract

Organic anion transporting polypeptide 1B3 (OATP1B3, SLCO1B3) is normally expressed in hepatocytes. In this study, we showed frequent overexpression of OATP1B3 in colorectal adenocarcinomas. Quantitative reverse transcription-PCR analysis of 17 colon tumors indicated tumoral overexpression of OATP1B3 by approximately 100-fold, compared with 20 normal colon samples (P < 0.0001). Using immunohistochemistry on a tissue microarray containing 93 evaluable colon tumor specimens, we detected immunostaining of OATP1B3 in 75 colon adenocarcinomas (81%) and no immunostaining in normal samples. To determine the functional effects of OATP1B3 expression on drug-induced apoptosis, we used camptothecin and oxaliplatin on a panel of colorectal cancer cell lines stably overexpressing OATP1B3. The results indicated that OATP1B3 overexpression enhanced cell survival in RKO, HCT-8, and HCT116(p53+/+) cells that harbor wild-type p53 but not in Caco-2 and HCT116(p53-/-) cells that lack p53, compared with the respective empty vector controls (P < 0.01). The terminal deoxynucleotidyl transferase-mediated nick-end labeling assay confirmed that HCT116(p53+/+) cells overexpressing OATP1B3 had significantly lower apoptotic levels compared with empty vector control (P < 0.001). The overexpression of OATP1B3 reduced the transcriptional activity of p53, with subsequent reductions in transcript and protein levels of its downstream transcription targets (P21WAF1 and PUMA). Overexpression of a point mutation (G583E) variant of OATP1B3 lacking transport activity did not confer an antiapoptotic effect or affect p53 transcriptional activity, suggesting that the antiapoptotic effect of OATP1B3 may be associated with its transport activity. Taken together, our results suggest that OATP1B3 overexpression in colorectal cancer cells may provide a survival advantage by altering p53-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074900      PMCID: PMC2605661          DOI: 10.1158/0008-5472.CAN-08-1984

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

Authors:  E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka
Journal:  Science       Date:  2000-05-12       Impact factor: 47.728

Review 2.  Poly(ADP-ribosylation) and apoptosis.

Authors:  A I Scovassi; G G Poirier
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 3.  No PUMA, no death: implications for p53-dependent apoptosis.

Authors:  Jian Yu; Lin Zhang
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

4.  Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells.

Authors:  Takashi Nozawa; Masato Suzuki; Hikaru Yabuuchi; Masanori Irokawa; Akira Tsuji; Ikumi Tamai
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.

Authors:  T Abe; M Unno; T Onogawa; T Tokui; T N Kondo; R Nakagomi; H Adachi; K Fujiwara; M Okabe; T Suzuki; K Nunoki; E Sato; M Kakyo; T Nishio; J Sugita; N Asano; M Tanemoto; M Seki; F Date; K Ono; Y Kondo; K Shiiba; M Suzuki; H Ohtani; T Shimosegawa; K Iinuma; H Nagura; S Ito; S Matsuno
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 6.  Genetic pathways in colorectal and other cancers.

Authors:  M Ilyas; J Straub; I P Tomlinson; W F Bodmer
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

Review 7.  Genetic and epigenetic alterations in colon cancer.

Authors:  William M Grady; Sanford D Markowitz
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

Review 8.  Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.

Authors:  Bruno Hagenbuch; Peter J Meier
Journal:  Pflugers Arch       Date:  2003-10-25       Impact factor: 3.657

9.  Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin.

Authors:  Oscar Briz; Maria A Serrano; Rocio I R MacIas; Javier Gonzalez-Gallego; Jose J G Marin
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

10.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.

Authors:  Xing-Jie Liang; Ding-Wu Shen; Susan Garfield; Michael M Gottesman
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  49 in total

1.  Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Authors:  Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 2.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

4.  Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines.

Authors:  Satoki Imai; Ryota Kikuchi; Yuri Tsuruya; Sotaro Naoi; Sho Nishida; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2013-06-28       Impact factor: 4.200

5.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

Review 6.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

7.  Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.

Authors:  Jiezhong Chen; Xu-Feng Huang; Liang Qiao; Andrew Katsifis
Journal:  J Gastrointest Oncol       Date:  2011-03

Review 8.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

Review 9.  Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.

Authors:  Ioannis Sainis; Demosthenes Fokas; Katerina Vareli; Andreas G Tzakos; Valentinos Kounnis; Evangelos Briasoulis
Journal:  Mar Drugs       Date:  2010-03-15       Impact factor: 5.118

Review 10.  Oestrogen and colorectal cancer: mechanisms and controversies.

Authors:  Paul A Foster
Journal:  Int J Colorectal Dis       Date:  2013-01-15       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.